Salarius Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Decoy Therapeutics Inc. is holding a special meeting on September 14, 2026, to seek shareholder approval for the issuance of shares upon exercise of Milestone Warrants and to reduce authorized shares.
Decoy Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 14, 2026, to elect directors, vote on executive compensation, and ratify auditor appointment.
Decoy Therapeutics Inc. is calling a special meeting on February 24, 2026, to seek stockholder approval for a new equity incentive plan and a reverse stock split aimed at meeting Nasdaq's listing requirements following its merger.
Salarius Pharmaceuticals, Inc. has supplemented its definitive proxy statement, announcing the adjournment of its 2025 Annual Meeting to December 31, 2025, and the engagement of Alliance Advisors for proxy solicitation.
Salarius Pharmaceuticals, Inc. has filed a Definitive Proxy Statement with the SEC, indicating its role as the registrant.
Salarius Pharmaceuticals, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 19, 2025, to vote on director elections, executive compensation, and auditor ratification.
Salarius Pharmaceuticals, Inc. has filed a Definitive Proxy Statement (DEFA14A) with the U.S. Securities and Exchange Commission.
Salarius Pharmaceuticals, Inc. is calling a Special Meeting of Stockholders to vote on a reverse stock split to regain Nasdaq compliance and to approve the issuance of shares under a $10 million equity line of credit, which could lead to substantial shareholder dilution.
Salarius Pharmaceuticals is calling a special meeting of stockholders to vote on a reverse stock split and an equity issuance to maintain its Nasdaq listing and fund operations.
Salarius Pharmaceuticals has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.
Salarius Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on December 20, 2024, to vote on director elections, executive compensation, and auditor ratification.
Salarius Pharmaceuticals has filed a definitive proxy statement with the SEC.
Salarius Pharmaceuticals is asking stockholders to approve a reverse stock split to increase its stock price and maintain its Nasdaq listing.